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Abstract
Purpose Glioblastoma (GBM) is the most common invasive malignant brain tumour in adults. It is traditionally investigated 
in vitro by culturing cells as a monolayer (2D culture) or as neurospheres (clusters enriched in cancer stem cells) but neither 
system accurately reflects the complexity of the three-dimensional (3D) chemoresistant microenvironment of GBM.
Materials and methods Using three GBM cell-lines (U87, U251, and SNB19), the effect of culturing cells in a Cultrex-based 
basement membrane extract (BME) [3D Tumour Growth Assay (TGA)] on morphology, gene expression, metabolism, and 
temozolomide chemoresistance was investigated.
Results Cells were easily harvested from the 3D model and cultured as a monolayer (2D) and neurospheres. Indeed, the 
SNB19 cells formed neurospheres only after they were first cultured in the 3D model. The expression of CD133 and OCT4 
was upregulated in the neurosphere and 3D assays respectively. Compared with cells cultured in the 2D model, cells were 
more resistant to temozolomide in the 3D model and this resistance was potentiated by hypoxia.
Conclusion Taken together, these results suggest that micro-environmental factors influence GBM sensitivity to temozolo-
mide. Knowledge of the mechanisms involved in temozolomide resistance in this 3D model might lead to the identification 
of new strategies that enable the more effective use of the current standard of care agents.
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Introduction
Glioblastoma is a devastating primary brain tumour. It is het-
erogeneous in nature and has a distinct cell of origin which 
makes it challenging to manage [1]. Temozolomide is the 
standard-of-care chemotherapy for glioblastoma [2]. How-
ever, most patients with glioblastoma die of the disease in 
less than 1 year after diagnosis as a result of chemoresistance 
associated with a cancer stem cell population and the topo-
graphically diffuse nature of the tumour [3]. To complicate 
this challenge, preclinical models that faithfully recapitulate 
relevant aspects of GBM biology in vitro have still not been 
established.
Tumour cells, including glioblastoma, are traditionally 
cultured in vitro on a plastic substrate, with an oxygen ten-
sion of 20%. However, the oxygen tension in GBM in vivo 
ranges from 0.1 to 10% [4]. Many studies do not take into 
account the physiologically relevant oxygen tension [5] as 
well as the changes in the extracellular matrix which can 
affect biological properties like proliferation and motility 
when investigating GBM cell in vitro [6].
Pre-clinical testing of drugs has largely relied on either 
two-dimensional (2D) in vitro cell models or animal studies. 
However, data from the 2D cultures are largely unreliable, 
as cells cultured in this model are not a true representa-
tive of the in vivo tumour microenvironment and, animal 
studies, as a result of interspecies differences, fail to fully 
recapitulate the response to drugs in humans with about 
95% of anti-cancer drug candidates failing to make it to 
the clinic, thereby wasting significant time and resources 
[7]. The neurosphere assay is an acceptable 3D model for 
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maintaining glioblastoma in vitro [8–10]. Although this 
assay has undoubtedly been regarded as the gold standard 
assay that selects for stem cell populations, it has a major 
drawback of allowing cells to form their own niche, with 
more differentiated cells positioned at the center than on the 
surface as well as containing a mixed population of cells and 
a small number of true stem cells [11].
3D cultures are now required as cells cultured in the 2D 
monolayers display aberrant cell–cell interactions [12]. As 
such, most of the conclusions from this system of culture 
do not accurately apply to the tumours in vivo. Therefore, 
3D in vitro culture systems offer more realistic cell–cell and 
cell–matrix interactions that are more physiological provid-
ing a better alternative to the 2D systems [13, 14].
Recently, a 3D model based on polystyrene scaffold has 
been used to predict drug-radiation combination for glioblas-
toma [15]. Furthermore, glioblastoma tumour-initiating cells 
have been successfully maintained in a microscale alginate 
hydrogel tubes (or AlgTubes) that allows affordable cost for 
drug discovery [16].
To develop a 3D in vitro culture system for glioblas-
toma which will allow routine drug testing and molecu-
lar manipulation, e.g. gene knockdown, glioblastoma cell 
lines were established in a Cultrex-based 3-Dimensional 
Tumour Growth Assay (3D-TGA) that allows single cells to 
be extracted for further culturing. With this system, it was 
also possible to culture cells in a hypoxic tumour microen-
vironment (TME). The 2D and 3D models were compared 
to describe morphology, glioblastoma stem cell markers, 
metabolism as well as temozolomide chemosensitivity.
Taken together, the current results suggest that micro-
environmental factors influence GBM cell biology. The 
3D assay could be used to further characterize GBM cells, 
including potential stem cells, and the pathways through 
which the tumour microenvironment influences their char-
acteristics and numbers, including their drug resistance and 
ability to invade/ metastasize.
Materials and methods
Cell‑lines
U87 cells, from European Type Culture Collection (ECCC) 
while U251 and SNB19 cells from National Cancer Institute, 
NCI60, were grown in normoxic (20% oxygen) or hypoxic 
(1% oxygen) conditions as standard 2D culture and as a 
Cultrex-based 3D culture.
The 3D‑TGA 
This was performed as previously described [14]. Briefly, 
the Cultrex basement membrane extract (BME) (Trevigen) 
was diluted to a concentration of 3 mg/ml on ice using 
phenol red-free modified RPMI (Life Technologies). The 
cells were resuspended at appropriate seeding density into 
a black-walled, low-adherent, clear-bottom 96-well plates 
(BrandTech) prewarmed to 37 °C.
Neurosphere culture
Neurosphere cultures were maintained in 128 ml High Glu-
cose Dulbecco’s Modified Eagle’s Medium (Invitrogen, UK) 
in which 116 ml F12 Ham (Invitrogen, UK) was added and 
supplemented by 10 ml B27 supplement (Invitrogen, UK), 
100 µg/ml FGF (Invitrogen, UK) and 100 µg/ml EGF (Invit-
rogen, UK) as well as 100 mg/ml Heparin (Sigma-Aldrich), 
at 37 °C in a 5%  CO2 and humidified atmosphere. Cells were 
seeded in a 24-well plate at a density of 20,000 cells/well.
The culture of cells in a hypoxia chamber
The Invivo2 400 hypoxia workstation (Ruskinn Technol-
ogy LTD) was used to set oxygen concentration at 1%. The 
chamber was accessed through an Ezee sleeve and purged 
with vacuum and gas pedal. The chamber which is set at 5% 
 CO2 at 37 °C is attached to a nitrogen cylinder which helps 
to maintain oxygen concentration in the chamber.
Quantitative real‑time PCR
Gene expression was assessed using real-time RT-PCR and 
data expressed relative to the housekeeping gene, HPRT 
as previously reported [14]. The expression of CD133 and 
OCT4, which are commonly used to define the CSC-like 
population in brain tumours, were detected using SYBR 
Green (Eurogentec) and calculated using the 2−ΔΔCt method. 
The primer sequences used were: CD133 forward: 5′-CAA 
TCT CCC TGT TGG TGA TTTG-3′ and CD133 reverse: 
5′-ATC ACC AGG TAA GAA CCC GGA-3′; OCT4 forward: 
5′-GTT GGA GAA GGT GGA ACC AA-3′ and OCT4 reverse: 
5′-CTC CTT CTG CAG GGC TTT C-3′.
Drug sensitivity assays
Temozolomide was dissolved in DMSO to a final concentra-
tion of 100 mM. Various concentrations ranging from 5 to 
1500 µM was applied to cells in triplicate wells. The cells 
were exposed to the drugs for 3 days before final endpoint 
reading using the Alamar Blue assay. The Alamar Blue assay 
[Invitrogen; 10% (v/v), 37 °C for 1 h] was used both as an 
indicator of metabolic function and drug sensitivity using a 
fluorescent plate reader (Flex-Station II, Molecular Devices, 
CA, USA). Drug sensitivity was calculated as a percentage 
of matched untreated control and  IC50 curves were plotted 
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and values determined using GraphPad Prism 6 (GraphPad 
Software Inc., USA; nonlinear curve fit of Y = 100/(1 + 10(Lo
gIC50−X) × hillslope).
Statistics
Students-test from GraphPad Prism, version 6 was used to 
analyze all data. Data were analyzed with either t-test or 
one-way ANOVA (Turkey’s multiple comparison test).
Results
GBM cultured in the 3D model was viable and could 
be re‑cultured as 2D monolayers or neurospheres
It has previously been demonstrated that the 3D model 
allows the culture of glioblastoma cells [14]. To know if 
cells cultured in the 3D can be subcultured, U251, U87 and 
SNB19 cells maintained in the 2D and 3D models were har-
vested and cultured as neurospheres.
It was noted that only U251 (Fig. 1a) and U87 (Supp 
Fig. 1) cells formed neurospheres from the 2D model. Upon 
harvest from the 3D model, U251 cells formed a monolayer 
of cells and neurospheres (Fig. 1a). These neurospheres 
could be maintained for more than 6th generation (data not 
shown). Notably, the SNB19 cells did not form neurospheres 
after being maintained as a 2D monolayer (Fig. 1b). How-
ever, following culture in the 3D model, they formed neuro-
spheres as well as monolayers of cells (Fig. 1b) indicating 
that culturing in the 3D model could influence the stem cell 
population to form neurospheres. Although the diameter of 
neurospheres formed when cells were first cultured in the 
3D model was smaller than those formed when the cells 
were first cultured in the 2D model, this was not significant 
(Fig. 1c).
Expression of stem cell markers, CD133 and OCT4 
in the 2D‑, 3D‑ and neurosphere assays
To determine the effect of the microenvironment on the 
expression of glioblastoma stem cell markers, we examined 
the mRNA expression of CD133 and OCT4 in the cells cul-
tured in the 3D assay and cells cultured as 2D (3D to 2D) 
and neurospheres (3D to neurosphere) following extraction 
from the 3D assay (Fig. 1). Our result showed that CD133 
expression was higher in the neurosphere assay compared 
to 2D and 3D assays with a significant upregulation in the 
U251 and SNB19 cells (Fig. 2; Table 1). Surprisingly, OCT4 
mRNA expression was significantly upregulated in the cells 
cultured in the 3D assay compared to when the cells were 
recultured as 2D or neurospheres (Fig. 2; Table 1). This 
result suggests that the microenvironment plays an important 
role in the expression of different stem cell markers. It also 
indicates that different culture conditions can modulate the 
expression glioblastoma stem cell population.
Metabolism pattern differs in the 3D model 
when compared with cells cultured in 2D 
in normoxia and hypoxia
After establishing that GBM cells were viable in the 3D 
model and that they can be recultured, it was important 
to understand the influence of culture in the 3D model on 
metabolism as metabolism affects chemosensitivity. To 
achieve this, U251 and SNB19 cells were cultured in 2D 
and 3D in normoxia or hypoxia. The metabolic pattern as 
observed with the AlamarBlue assay in the 2D and 3D mod-
els was remarkable. After 2 days in the 2D model, meta-
bolic activity from the readout was stabilized (Fig. 3a–c) 
and gradually decreasing in the SNB19 cells cultured in 
hypoxia (Fig. 3d). However, in the 3D model, a reduced 
metabolic readout was observed which gradually increased 
(Fig. 3a–d), with the U251 cells cultured in normoxia dis-
playing constant reading between day 4 and 5 (Fig. 3a). In 
the U87 cells, metabolic activity was stabilised at day 3 in 
2D assay but gradually increased from day 3 in the 3D assay 
(Supp Fig. 2). Attempt to understand the protein kinetics via 
western blot was technically difficult because of the time it 
took to harvest cells from the 3D matrix [14].
The 3D confers resistance to temozolomide (TMZ) 
which was potentiated in hypoxia
To determine the role of the 3D tumour microenvironment 
in resistance to TMZ, GBM cells (U87, U251 and SNB19) 
were cultured in the 2D and 3D assays in normoxia and 
hypoxia. We found that cells cultured in the 3D assay were 
significantly more resistant to TMZ than those maintained 
as 2D in both normoxia and hypoxia with as high as fivefold 
in the U251 cells (Fig. 4a and c).
To further evaluate the role of different microenviron-
ment in TMZ resistance, the U251 cells were used as 
model because they readily form neurospheres compared 
to the U87 and the SNB19 cells do not form neurospheres 
when they are first maintained as 2D. Two sets of U251 
cells were exposed to hypoxia and a third set was main-
tained in normoxia as a control. The set maintained in 
normoxia was cultured as either 2D (monolayer) or neuro-
sphere. After 24 h in hypoxia, cells in all sets were treated 
with temozolomide. From the two sets initially exposed to 
hypoxia, one set was immediately transferred to normoxia 
(24 h pre-exposure to hypoxia-Pre-H) (Fig.  4b). After 
72 h of treatment with temozolomide, it was surprisingly 
found that exposure to hypoxia did not have any significant 
change to the resistance of temozolomide in the U251 cells 
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Fig. 1  GBM cells presents distinct morphological feature in 3D and 
viable cells can be harvested from 3D and re-cultured as 2D and neu-
rospheres. U251 (a) and SNB19 (b) cells were cultured in 2D and 3D 
models. The cells were harvested from these models and recultured 
as neurospheres.N = 3. Additionally, cells from the 3D models were 
recultured as 2D. c The diameter of neurospheres formed when cells 
were first cultured in the 2D and 3D model and recultured as neuro-
spheres. Pictures were taken with a T9 Nikon Microscope. Scale bar 
= 100 µm. Magnification × 10
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(Fig. 4b). In addition, stem cell condition, i.e. the cells 
cultured as neurosphere, did not influence the resistance 
of cells to temozolomide (Fig. 4b).
To validate that the increase in resistance was an effect 
of the 3D environment, cells were first cultured as 3D, 
after 48 h, the cells were harvested from the 3D matrix 
and cultured as 2D and then treated with temozolomide. 
Fig. 2  Differences in the mRNA expression of CD133 and OCT4 in 
the 2D, 3D and neurosphere assays. U251 (a and b), U87 (c and d) 
and SNB19 (e and f) cells were cultured as 3D. At day 3, the cells 
were harvested from the 3D matrix and recultured as either 2D (3D 
to 2D) or as neurospheres (3D to NS). qRT-PCR was used to quantify 
the levels of respective genes at day 3 (3D and 3D to 2D) and day 7 
(3D to NS). The error bar represents standard error of mean from 3 
independent experiments. One way ANOVA from Prism7 was used 
for statistical comparison. *p < 0.05, **p < 0.01, ****p < 0.0001. NS 
neurosphere
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Table 1  Fold difference of CD133 and OCT4 mRNA expression
Following the culture of U251, U87 and SNB19 cells in the 3D assay, the cells were harvested from the 3D matrix and recultured as either 2D 
(3D to 2D) or as neurospheres (3D to NS). The fold difference relative to cells cultured in the 3D assay (3D to 2D and 3D to NS) is as indicated. 
In addition, the expression of genes in neurosphere NS assay relative to the 3D cells recultured as 2D is as indicated (2D vs. NS). The p values 
are as shown in brackets from One way ANOVA from Prism7. N = 3. NS not significant
CD133
3D to 2D 2D versus NS 3D to NS
Fold difference
 U251 2.3 (NS) 5.6 (p = 0.0078) 2.5 (p = 0.003)
 U87 2.8 (NS) 34.9 (NS) 12.6 (NS)
 SNB19 1.4 (NS) 8.4 (p = 0.0167) 6.0 (p = 0.0142)
OCT4
3D to 2D 2D versus NS 3D to NS
Fold difference
 U251 556.9 (p < 0.0001) 2.1 (NS) 268.6 (p < 0.0001)
 U87 4.1 (p = 0.0123) 1.2 (NS) 5.1 (p = 0.0099)
 SNB19 700.2 (p = 0.01) 6.3 (NS) 112.0 (p = 0.0103)
Fig. 3  Metabolic activity of cells in the 2D and 3D assays in nor-
moxia and hypoxia: U251 (a and b) cells and SNB19 cells (c and d) 
were cultured in the 2D (grey) and 3D (black) assays. At day 0 of set 
up, baseline reading was taken with the Alamar Blue assay after the 
cells had settled and one set of the cells was maintained in normoxia 
(left panel) while the other group was transferred to hypoxia (right 
panel). The metabolic activity of the cells was monitored for 5 days. 
The error bars represent the average fluorescence from 2 independent 
experiments. The graph was plotted relative to day 0
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It was found that the  IC50 values returned to baseline (not 
shown).
Discussion
The realization that there is an obvious disconnect between 
in vitro culture and in vivo milieu has given researchers the 
reason to develop physiologically relevant in vitro assays 
that better reflect the tumour-microenvironment. The 2D 
monolayer culture system, though spontaneous and easily 
manipulated, has generated scientific concerns, as some drug 
agents that have been successfully classed as promising in 
this system have become clinically irrelevant, with only 
about 10% making it to the clinic leading to money and time 
wastage [7]. For instance, it has been shown that GSCs rely 
on kinases in the 2D substrates but not in a 3D environment 
[17]. Furthermore, many key players of the tumour-micro-
environment are omitted in the 2D assays [18, 19]. As such, 
most conclusions from the 2D experiments do not take into 
account the influence of the tumour-microenvironment [20]. 
In this study, we described a novel glioblastoma 3D in vitro 
assay where hypoxia was incorporated to determine gene 
expression, cancer cell metabolism and chemoresistance.
We observed that the SNB19 cells formed neurospheres 
only when they were first cultured in the 3D assay. This may 
be as a result of cell reprograming as the tumour microenvi-
ronment can reprogram cells towards a stem-like phenotype 
[21, 22]. Furthermore, neurospheres formed from cells first 
cultured as 2D monolayers were bigger than those formed 
Fig. 4  Sensitivity of GBM cells to temozolomide in the 2D, 3D and 
neurosphere assays in normoxia and hypoxia. a Following the cul-
ture of U87, U251 and SNB19 cells in the 2D and 3D models under 
normoxic (N) and hypoxic (H) conditions, the cells were treated with 
temozolomide and final viability was determined by AlamarBlue 
assay while GraphPad prism6 software was used to calculate  IC50 
values. The error bar represents standard error of the mean (SEM) 
from an average of 3 independent experiments. T-test from Graph-
Pad prism6 was used for comparison. *Indicates that  IC50 was not 
achieved and highest concentration was used. b U251 cells were 
cultured in the 2D model in three sets. At day 0 of setup, two sets 
were transferred to hypoxia while the third set and neurospheres were 
maintained in normoxia as a control. At 24  h exposure to hypoxia, 
the cells in all sets were treated with temozolomide. One set of cells 
was then maintained in hypoxia; the other set was transferred to nor-
moxia (Pre-H) while the third set was maintained in normoxia. The 
final viability of the cells was determined by AlamarBlue assay while 
GraphPad prism6 software was used to calculate  IC50. N = 4. c Fold 
difference of temozolomide resistance in the 2D and 3D models in 
normoxia and hypoxia. p value is as indicated
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from cells generated from the 3D assays. Although, all neu-
rospheres do not arise from stem cells [23], our observation 
could be related to the fact that true stem cells grow slowly 
than their differentiated progeny [24, 25].
It may seem that cells cultured as either 2D, 3D, or neu-
rospheres are at different stages of lineage differentiation as 
seen by stem cell gene expression. While CD133 expres-
sion was upregulated in the neurosphere assay, OCT4 was 
upregulated in the 3D assay. Our result supports a system 
where multiple stem cell markers could be used to select 
stem cell population [26, 27].
Although, we did not use special markers, to immediately 
distinguish between stem cells and their transit amplifying 
progeny, it is crucial to evaluate which CD133 positive pop-
ulation constitute true stem cells population as the strengths 
and limitations of these systems (3D and neurosphere) need 
to be understood.
Metabolism plays a crucial role in GBM progression [28, 
29] and it has been found that metabolic markers are upregu-
lated in hypoxic tumour microenvironment [30, 31]. Our 
current result also indicates that there was an initial decrease 
in metabolism in the 3D-TGA compared to the cells cultured 
as 2D. This is consistent with the findings of Smith et al. 
[32] who used magnetic resonance spectroscopy to reveal 
differential metabolic profiles in 2D and 3D conditions. 
When cells are cultured in 3D, different zones of prolifera-
tion are introduced as a result of oxygen, nutrient and waste 
gradient. However, in the 2D assay, the rate of proliferation 
of cells is relatively uniform across the plate making growth 
of cells as 2D relatively faster than as 3D [33].
All our cells showed an initial lag in the 3D when com-
pared to cells in the 2D, which is consistent with Kievit and 
colleagues who reported an initial lag of glioblastoma cells 
in the 3D chitosan-alginate scaffold [34].
Temozolomide (TMZ) has improved the prognosis of 
glioblastoma patients with its ability to cross the blood–brain 
barrier (BBB) and a bioavailability of 100% [35]. It has pre-
viously been observed that regions of hypoxia are prevalent 
in glioblastoma and that hypoxia selects for a highly chem-
oresistant phenotype in glioblastoma [36]. Most cells are 
resistant to chemotherapy in hypoxia [14].
However, when glioblastoma cells were cultured under 
a hypoxic environment in the 2D model, there was no 
significant difference in temozolomide resistance when 
compared with cells cultured in the same 2D model but 
under normoxic condition. Furthermore, when cells were 
cultured as neurospheres, which select for stem cell popu-
lation,  IC50 values were similar to those obtained in the 
2D model. However, when the cells were cultured in the 
3D model, we found that glioblastoma cells were signifi-
cantly resistant to temozolomide and this was potenti-
ated by hypoxia. It is important to highlight that hypoxia 
which was of no consequence in the 2D model played 
an important role in the 3D model implying that our 3D 
model may recapitulate in vivo temozolomide resistance 
and may allow for the study of components of the micro-
environment that are involved in temozolomide resistance.
Cells cultured in the 3D model make contact with 
each other and with the matrix. The basement membrane 
extract used in this study is rich in collagen 4. In line with 
this, collagen 4 has been shown to promote the resistance 
of cells in vitro. Collagen 4 staining was also observed 
in vivo ovarian tumors were they correlated with tumor 
grade [37]. Laminin is another component of this 3D 
model. Interestingly, gene microarray analysis has shown 
that the α4 chain of laminin, which is a major blood vessel 
component, is overexpressed in human glial tumors [38]. 
While laminin-9 was associated with an astrocytoma of 
lower grades, high levels of laminin-8 were found in GBM 
and were associated with patient survival [39]. Moreo-
ver, brain tumors recurred faster in patients after standard 
therapy if laminin 8 is overexpressed and these patients 
had shorter survival time [40]. These results suggest that 
tumor cells may directly remodel their microenvironment 
to increase their survival in the presence of chemothera-
peutic drugs and offers the opportunity to correlate base-
ment membrane proteins with drug resistance in future 
experiments.
Thus, these finding implies that the resistance of GBM 
cells to temozolomide may not be adequately understood in 
isolation of components of the TME (in this case, hypoxia 
and components of the 3D model) because interaction of 
GBM cells with basement membrane proteins was enough 
to enhance drug resistance suggesting that stem cell popula-
tions may not be the only factor facilitating the resistance 
of glioblastoma to temozolomide. Indeed, downregulation 
of CD133 did not sensitise glioblastoma cells to temozolo-
mide [14] but OCT4 expression is associated with tumour 
malignancy in astrocytic brain tumours [41] and indicates 
negative prognosis in Cervical Squamous Cell Carcinoma 
[42]. Moreover, knockdown of OCT4 increases the sensitiv-
ity to temozolomide in glioma-initiation cells [43] making it 
a target for the development of future therapeutic strategies 
[44]. Our 3D model reveals upregulation in OCT4 mRNA. 
These cells, along with those that co-express CD133 could 
be further exploited for future studies.
Overall, this study has demonstrated the possibility of 
maintaining and manipulating glioblastoma cells in vitro in 
a Cultrex-based 3D model. It was found that cells cultured in 
the 3D model behaved differently to their 2D counterparts, 
both morphologically and in response to chemotherapy. 
This model tended towards a highly-resistant and stem-like 
phenotype suggesting that it could be a highly-predictive 
surrogate model for in vitro high-throughput drug testing 
to understand and overcome temozolomide resistance in 
glioblastoma.
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